Fineline Cube

Follow:
14452 Articles
Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children
Others

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
CompanyDrug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

CompanyDeals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Others

Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects

Company

RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal

Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance
Company

Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance

CompanyDrug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

CompanyDeals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

CompanyR&D

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases